Impact of neoadjuvant relugolix on patient-reported sexual function and bother

Impact of neoadjuvant relugolix on patient-reported sexual function and bother

IntroductionSexual function following local treatment for prostate cancer is an important quality of life concern. Relugolix is a novel oral GnRH receptor antagonist used in combination with radiation therapy in the treatment of unfavorable prostate cancer. It has been shown to achieve rapid and pro...

Full description

Bibliographic Details
Main Authors: Jessica Y. Hsueh, Lindsey Gallagher, Min Ji Koh, Shaine Eden, Sarthak Shah, Markus Wells, Malika Danner, Alan Zwart, Marilyn Ayoob, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Rachel Rubin, Sean P. Collins
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
stereotactic body radiation therapy (SBRT)
relugolix
sexual function
bother
androgen deprivation therapy (ADT)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1377103/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1377103/full

Similar Items